NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

BCAX

Bicara Therapeutics Inc

Jul 03 • 02:20PM ET

9.03

Dollar change -0.17
Percentage change -1.85	%

Healthcare • Biotechnology • USA • NASD

Held by: IWM VTI VXF IWN VTWO SCHA FESM VHT SBIO TMSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.70	Insider Own	39.92%	Shs Outstand	54.53M	Perf Week	2.50%
Market Cap	492.46M	Forward P/E	-	EPS next Y	-2.65	Insider Trans	-0.43%	Shs Float	32.77M	Perf Month	-17.98%
Enterprise Value	30.99M	PEG	-	EPS next Q	-0.54	Inst Own	62.40%	Short Float	15.52%	Perf Quarter	-31.90%
Income	-92.33M	P/S	-	EPS this Y	42.88%	Inst Trans	14.09%	Short Ratio	5.63	Perf Half Y	-46.88%
Sales	0.00M	P/B	1.07	EPS next Y	-14.38%	ROA	-	Short Interest	5.08M	Perf YTD	-48.16%
Book/sh	8.42	P/C	1.07	EPS next 5Y	11.95%	ROE	-	52W High	28.09 -67.85%	Perf Year	-
Cash/sh	8.47	P/FCF	-	EPS past 3/5Y	-30.70% -	ROIC	-20.12%	52W Low	7.80 15.77%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.85% 8.57%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.96	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	24.62	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	39.42	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	24.62	EPS Q/Q	-194.30%	SMA20	-10.34%	Beta	-	Target Price	32.60
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-24.10%	Rel Volume	0.28	Prev Close	9.20
Employees	55	LT Debt/Eq	0.00	Earnings	May 13 BMO	SMA200	-43.17%	Avg Volume	902.74K	Price	9.03
IPO	Sep 13, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-63.86% -	Trades		Volume	248,783	Change	-1.85%

Date	Action	Analyst	Rating Change	Price Target Change
May-23-25	Upgrade	Wells Fargo	Underweight → Equal Weight	$8
Apr-17-25	Initiated	Wells Fargo	Underweight	$8
Feb-06-25	Initiated	Wedbush	Outperform	$31
Dec-06-24	Initiated	H.C. Wainwright	Buy	$42
Nov-05-24	Initiated	Rodman & Renshaw	Buy	$48
Oct-08-24	Initiated	TD Cowen	Buy
Oct-08-24	Initiated	Stifel	Buy	$47
Oct-08-24	Initiated	Morgan Stanley	Overweight	$35
Oct-08-24	Initiated	Cantor Fitzgerald	Overweight

Jun-11-25 04:05PM	Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors (GlobeNewswire) -5.56%
Jun-03-25 04:01PM	Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire) +11.21%
Jun-01-25 01:12PM	Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 (GlobeNewswire)
May-29-25 06:54AM	ASCO25: Merus wins in head-to-head with Bicara for head and neck cancer (Clinical Trials Arena)
May-27-25 01:59PM	Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update (Insider Monkey) +7.66%
09:14AM	Loading…
May-26-25 09:14AM	Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients (Insider Monkey)
May-23-25 10:15AM	Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics (Investor's Business Daily) -40.80%
May-22-25 05:00PM	Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting (GlobeNewswire) +7.33%
May-13-25 07:30AM	Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -8.10%
Apr-28-25 04:01PM	Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025 (GlobeNewswire)
Apr-23-25 10:00AM	Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +12.23%
Apr-19-25 06:22AM	Bicara: Innovative Precision Tumor Targeting (Seeking Alpha)
Mar-27-25 07:30AM	Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-25-25 04:45PM	Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025 (GlobeNewswire) -5.58%
Feb-24-25 04:01PM	Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
04:01PM	Loading…
Feb-11-25 04:01PM	Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (GlobeNewswire)
Jan-27-25 08:00AM	Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Jan-08-25 10:16AM	Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia (Clinical Trials Arena)
Nov-12-24 07:30AM	Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -7.30%
Nov-11-24 04:01PM	Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference (GlobeNewswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks)
Oct-08-24 10:44AM	MBX Biosciences earns Buy rating at three investment firms (Investing.com) -7.77%
Sep-23-24 07:05PM	RA Capital Management's Strategic Acquisition of Bicara Therapeutics Shares (GuruFocus.com)
Sep-19-24 01:13AM	TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc (GuruFocus.com)
Sep-18-24 03:01PM	FMR LLC Acquires New Stake in Bicara Therapeutics Inc (GuruFocus.com)
Sep-17-24 09:13AM	Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity (Pharmaceutical Technology) +6.53%
Sep-16-24 04:01PM	Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +8.54%
Sep-13-24 04:09PM	Biotech IPO Shares Climb in Debuts After Deals Upsized (Bloomberg)
12:19AM	Bicara Leads Trio of US Biotech IPOs Raising $703 Million (Bloomberg)
Sep-12-24 09:15PM	Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
07:02PM	Loading…
07:02PM	Three biotechs raise $700M in rare burst of IPO activity (BioPharma Dive)

Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company's bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Meisner Lara	Chief Legal Officer	Jun 16 '25	Option Exercise	5.45	15,829	86,268	15,829	Jun 18 05:12 PM
Meisner Lara	Chief Legal Officer	Jun 16 '25	Sale	10.43	15,829	165,096	0	Jun 18 05:12 PM
LARA S. MEISNER	Officer	Jun 16 '25	Proposed Sale	10.84	31,658	343,173		Jun 16 04:29 PM
Meisner Lara	Chief Legal Officer	Mar 14 '25	Option Exercise	5.45	79,146	431,346	79,145	Mar 18 06:35 PM
Meisner Lara	Chief Legal Officer	Mar 14 '25	Sale	12.90	79,146	1,021,211	0	Mar 18 06:35 PM
LARA S. MEISNER	Officer	Mar 14 '25	Proposed Sale	13.35	79,146	1,056,599		Mar 14 04:21 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Sep 16 '24	Buy	18.00	1,833,000	32,994,000	4,303,418	Sep 18 06:02 PM
Flynn James E	Possible Members of 10% Group	Sep 17 '24	Buy	18.00	70,000	1,260,000	897,587	Sep 17 06:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BCAX

Bicara Therapeutics Inc

Upgrade your FINVIZ experience